TrialCancer communications (London, England)2019

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).

Ji-Yeon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.